Eugene Ng
Retina Specialist · Honolulu, HINPI 1609021831
Payments from drug & device makers
Across 164 payments — averaging $62.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$3K
- AbbVie$2K
- Genentech USA, Inc.$1K
- Sight Sciences, Inc.$538
- Intuitive Surgical$407
- Glaukos Corporation$352
- plus $2K from 21 others
What the payments were for
- Travel & lodging$1,30913%
- Food & beverage$8,97287%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 34 | $3,326 |
| AbbVie(2 entities) | 35 | $1,880 |
| Genentech USA, Inc. | 31 | $1,425 |
| Sight Sciences, Inc. | 8 | $538 |
| Intuitive Surgical | 3 | $407 |
| Glaukos Corporation | 3 | $352 |
| Oyster Point Pharma, Inc. | 4 | $287 |
| Regeneron Healthcare Solutions, Inc. | 2 | $233 |
| Sun Pharmaceutical Industries Inc. | 10 | $213 |
| ANI Pharmaceuticals, Inc. | 3 | $191 |
| Dompe US, Inc. | 3 | $189 |
| Alimera Sciences, Inc. | 1 | $175 |
| LKC Technologies, Inc. | 2 | $143 |
| Novartis | 3 | $137 |
| Heidelberg Engineering, Inc. | 1 | $128 |
| Eyepoint US, Inc. | 5 | $108 |
| Mallinckrodt Hospital Products Inc. | 4 | $106 |
| Regeneron | 1 | $104 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $77 |
| Lumibird Medical Inc. | 1 | $65 |
| Dutch Ophthalmic, USA | 1 | $38 |
| Amgen | 2 | $36 |
| Apellis Pharmaceuticals, Inc. | 1 | $34 |
| Synergeyes, Inc. | 1 | $33 |
| Coherus Oncology, Inc. | 1 | $21 |
| Mallinckrodt Enterprises LLC | 1 | $20 |
| Kala Pharmaceuticals, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEN GLAUCOMA TREATMENT SYSTEM$1,163
- VABYSMO$992
- ARGOS$563
- Clareon$548
- DURYSTA$490
- Da Vinci Surgical System$401
- OMNI(R) SURGICAL SYSTEM (US)$368
- TYRVAYA$269
- Clareon PanOptix Pro$259
- EYLEA HD$226
- EYLEA$215
- Iluvien$175
- iDoseTR$175
- iDose$146
- Unity$146
- PURIFIED CORTROPHIN GEL$139
- NGENUITY$136
- SION SURGICAL INSTRUMENT$131
- Rocklatan$129
- Voyager DSLT$129
How this compares
Too few retina specialist providers in Hawaiito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 86 | $104,109 |
| Brimonidine Tartrate | 319 | $51,567 |
| RhopressaNetarsudil Mesylate | 81 | $48,973 |
| XiidraLifitegrast | 31 | $37,858 |
| Prednisolone Acetate | 353 | $19,924 |
| RocklatanNetarsudil Mesylat/Latanoprost | 29 | $19,332 |
| Latanoprost | 581 | $14,155 |
| VyzultaLatanoprostene Bunod | 18 | $14,066 |
| TyrvayaVarenicline Tartrate | 15 | $11,056 |
| LumiganBimatoprost | 16 | $10,126 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 469 | $8,983 |
| Ketorolac Tromethamine | 240 | $5,716 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 20 | $4,834 |
| Ofloxacin | 308 | $4,130 |
| Cyclosporine | 12 | $3,797 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P | $1,880 | $117,354114 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $287 | $11,05615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few retina specialist providers in Hawaiion file to place this against a meaningful peer group, so we don't.
Other retina specialist in Honolulu
- Anna ParlinHonolulu$17K
- Peter Hurlbut-MillerHonolulu$892
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.